Literature DB >> 2605789

Methimazole-induced agranulocytosis in Japanese patients with Graves' disease.

H Tamai1, Y Takaichi, T Morita, G Komaki, S Matsubayashi, K Kuma, R M Walter, L F Kumagai, S Nagataki.   

Abstract

We reviewed the records of approximately 7000 Japanese patients whose hyperthyroidism was treated with methimazole (MMI) alone. Four patients (Group I) developed agranulocytosis during a second course of MMI therapy and eight patients (Group II) during an initial course. Six patients (three in each group) received less than 30 mg MMI daily. Agranulocytosis occurred after more than 2 months of therapy (12 weeks-1 year) in five patients. Seven patients were less than 40 years of age. One patient displayed a gradual protracted development of agranulocytosis. These results indicate that agranulocytosis after MMI may occur irrespective of dose, age, duration of treatment, and with a second exposure.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2605789     DOI: 10.1111/j.1365-2265.1989.tb01424.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  12 in total

Review 1.  Diagnosis and management of Graves' disease.

Authors:  Jody Ginsberg
Journal:  CMAJ       Date:  2003-03-04       Impact factor: 8.262

2.  Safety of long-term antithyroid drug treatment? A systematic review.

Authors:  F Azizi; R Malboosbaf
Journal:  J Endocrinol Invest       Date:  2019-05-27       Impact factor: 4.256

3.  Thyrotoxicosis and antithyroid drugs.

Authors:  D Monakier; S Shilo
Journal:  Postgrad Med J       Date:  1997-06       Impact factor: 2.401

Review 4.  Adverse effects of thyroid hormone preparations and antithyroid drugs.

Authors:  L Bartalena; F Bogazzi; E Martino
Journal:  Drug Saf       Date:  1996-07       Impact factor: 5.606

Review 5.  Antithyroid drug-induced agranulocytosis: clinical experience with ten patients treated at one institution and review of the literature.

Authors:  M Meyer-Gessner; G Benker; S Lederbogen; T Olbricht; D Reinwein
Journal:  J Endocrinol Invest       Date:  1994-01       Impact factor: 4.256

6.  Successful treatment of methimazole-induced severe aplastic anemia by granulocyte colony-stimulating factor, methylprednisolone, and cyclosporin.

Authors:  Munehiro Honda
Journal:  ISRN Endocrinol       Date:  2011-04-10

7.  A patient with agranulocytosis following the discontinuation of methimazole treatment for 4 months: A case report.

Authors:  Xiao-Su Bai; Jing-Hai Liu; Shao-Mei Xiao
Journal:  Exp Ther Med       Date:  2014-06-30       Impact factor: 2.447

8.  Relationship between dose of antithyroid drugs and adverse events in pediatric patients with Graves' disease.

Authors:  Kie Yasuda; Yoko Miyoshi; Makiko Tachibana; Noriyuki Namba; Kazunori Miki; Yukiko Nakata; Toru Takano; Keiichi Ozono
Journal:  Clin Pediatr Endocrinol       Date:  2017-01-31

9.  Guidelines for the treatment of childhood-onset Graves' disease in Japan, 2016.

Authors:  Kanshi Minamitani; Hirokazu Sato; Hidemi Ohye; Shohei Harada; Osamu Arisaka
Journal:  Clin Pediatr Endocrinol       Date:  2017-04-22

10.  Development of Agranulocytosis after Discontinuation of Methimazole: An Unusual Case.

Authors:  Rıfkı Üçler; Murat Atmaca; Ömer Candar; Murat Alay; Burhan Göy; Erdal Kara; Mahfuz Turan; Yusuf Demir
Journal:  Case Rep Endocrinol       Date:  2015-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.